Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
Garcia-Rosa M, Abraham A, Bertaina A, Bhoopalan SV, Bonfim C, Cohen S, DeZern A, Louis C, Oved J, Pavel-Dinu M, Purtill D, Ruggeri A, Russell A, Sharma A, Wynn R, Boelens JJ, Prockop S. Garcia-Rosa M, et al. Among authors: dezern a. Cytotherapy. 2023 Jun;25(6):578-589. doi: 10.1016/j.jcyt.2023.02.007. Epub 2023 Mar 21. Cytotherapy. 2023. PMID: 36941149 Review.
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond.
Belbachir S, Abraham A, Sharma A, Prockop S, DeZern AE, Bonfim C, Bidgoli A, Li J, Ruggeri A, Bertaina A, Boelens JJ, Purtill D; Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy. Belbachir S, et al. Among authors: dezern ae. Cytotherapy. 2023 Dec 4:S1465-3249(23)01103-9. doi: 10.1016/j.jcyt.2023.11.004. Online ahead of print. Cytotherapy. 2023. PMID: 38054912
Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.
Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, Huo J, Dezern AE, Steppan D, Robey N, Holuba MJ, Cooke KR, Symons HJ. Klein OR, et al. Biol Blood Marrow Transplant. 2016 May;22(5):895-901. doi: 10.1016/j.bbmt.2016.02.001. Epub 2016 Feb 6. Biol Blood Marrow Transplant. 2016. PMID: 26860634 Free PMC article. Clinical Trial.
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines.
DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE. DeFilipp Z, et al. Transplant Cell Ther. 2023 Feb;29(2):71-81. doi: 10.1016/j.jtct.2022.11.014. Epub 2022 Nov 25. Transplant Cell Ther. 2023. PMID: 36436780 Free article. Review.
Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Imus PH, et al. Biol Blood Marrow Transplant. 2020 Dec;26(12):2306-2310. doi: 10.1016/j.bbmt.2020.09.018. Epub 2020 Sep 19. Biol Blood Marrow Transplant. 2020. PMID: 32961372 Free PMC article.
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis.
Jain T, Tsai HL, DeZern AE, Gondek LP, Elmariah H, Bolaños-Meade J, Luznik L, Fuchs E, Ambinder R, Gladstone DE, Imus P, Webster J, Prince G, Ghiaur G, Smith BD, Ali SA, Ambinder A, Dalton WB, Gocke CB, Huff CA, Gojo I, Swinnen L, Wagner-Johnston N, Borrello I, Varadhan R, Levis M, Jones RJ. Jain T, et al. Among authors: dezern ae. Transplant Cell Ther. 2022 May;28(5):259.e1-259.e11. doi: 10.1016/j.jtct.2022.02.004. Epub 2022 Feb 11. Transplant Cell Ther. 2022. PMID: 35158092 Free PMC article.
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF. Mishra A, et al. Among authors: dezern ae. J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11. J Clin Oncol. 2022. PMID: 35816664
The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition.
Gurbuxani S, Hochman MJ, DeZern AE, Shimamura A. Gurbuxani S, et al. Among authors: dezern ae. Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390026. doi: 10.1200/EDBK_390026. Am Soc Clin Oncol Educ Book. 2023. PMID: 37307513 Free article. Review.
Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.
DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston ND, Ambinder RF, Brodsky RA, Cooke K, Luznik L, Fuchs EJ, Bolaños-Meade J, Jones RJ. DeZern AE, et al. Biol Blood Marrow Transplant. 2020 Nov;26(11):2075-2081. doi: 10.1016/j.bbmt.2020.07.037. Epub 2020 Aug 18. Biol Blood Marrow Transplant. 2020. PMID: 32818556 Free article.
189 results